|
Meet The Professors: Oncologist and Nurse Investigators Consult on Challenging Cases of Actual Patients
OVERVIEW OF ACTIVITY
The comprehensive clinical management of both solid tumors and hematologic cancers is continuously evolving, with new research introducing the utility of novel systemic and supportive therapeutic agents maturing almost daily.
Breast and lung cancer, in isolation, comprise a significant proportion of routine oncology practice and are thus of particular relevance to ongoing education targeting the cross-functional treatment team. Although breast cancer may have a protracted natural history relative to tumors of the lung, both diseases are currently managed with a diverse array of antineoplastic agents, including cytotoxic chemotherapy and molecular-targeted or biologic agents, each with unique side effects and toxicities. In the case of breast cancer, hormonal therapy adds yet another layer of clinical management complexity that oncology care providers must be prepared to successfully address.
In the hematologic cancer space, the non-Hodgkin’s lymphomas (NHL), including chronic lymphocytic leukemia (CLL), and multiple myeloma (MM) are among the most prevalent diseases, and both have been the focus of recent clinical knowledge acquisition and resulting incremental treatment advances. This substantial progress necessitates learning opportunities to ensure that best-practice interventional and supportive management strategies are employed.
The integral role of oncology nurses in the communication and delivery of cancer care spans the psychosocial, supportive and therapeutic management spectra. These pivotal practitioners must be well versed in the evidence to effectively counsel their patients about treatment benefit, risk and impact on quality of life. This activity features group discussion with leading oncology nurses and medical oncologists reviewing the latest research developments in context with practical case application.
PURPOSE STATEMENT
To provide the perspectives of oncology nurses and medical oncologists regarding evidence-based treatment recommendations, rational supportive care algorithms and a review of the newest research developments affecting the care of patients with NHL/CLL, MM, breast cancer and lung cancer.
EDUCATIONAL OBJECTIVES
- Formulate strategies to educate patients with NHL or CLL about the benefits and risks of evidence-based treatment options, including chemotherapy, radioimmunotherapy, monoclonal antibodies, immunomodulators, proteasome inhibitors and stem cell transplant.
- Provide guidance to patients with active MM about the efficacy and safety of systemic regimens used in the transplant and nontransplant settings, including consolidation and maintenance approaches.
- Recognize the indications for hormonal, chemotherapeutic and/or biologic treatment of breast cancer, and explain the side effects associated with each.
- Communicate the benefits and risks of chemotherapy, tyrosine kinase inhibitors and biologic agents to patients with advanced non-small cell lung cancer (NSCLC) who are eligible for front-line, maintenance or subsequent systemic treatment.
- Develop a plan of care to address side effects, quality of life and medication adherence for patients with NHL/CLL, MM, breast cancer or lung cancer.
ACCREDIATION STATEMENT
This educational activity for 4.8 contact hours is provided by Research To Practice during the period of October 2010 through October 2011.
Research To Practice is an approved provider of continuing nursing education by the NJSNA, an accredited approver, by the American Nurses Credentialing Center’s Commission on Accreditation.
HOW TO USE THIS CNE ACTIVITY
This is an audio CNE program. This website contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Educational Assessment and Credit Form, as well as links to relevant abstracts and full-text articles.
To receive credit, participants should read the learning objectives and faculty disclosures, listen to the audio MP3s and complete the Post-test and Educational Assessment and Credit Form located at CME.ResearchToPractice.com. A statement of CNE credit will be issued only upon completion of the Post-test, with a score of 75 percent or better, and the Educational Assessment and Credit Form. Your statement of credit will be mailed to you within three weeks or may be printed online.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Ms McKenney had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Czuczman — Advisory Committee: Amgen Inc, Biogen Idec, Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation; Lectures: Biogen Idec, Genentech BioOncology. Ms Downs — Advisory Committee: GlaxoSmithKline; Speakers Bureau: Cephalon Inc, Genentech BioOncology, Millennium Pharmaceuticals Inc. Ms Goodrich — Advisory Committee: Cephalon Inc. Dr Gregory — Advisory Committee: Cephalon Inc; Consulting Agreements: Amgen Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Spectrum Pharmaceuticals Inc; Speakers Bureau: Cephalon Inc, Genentech BioOncology. Ms Faiman — Advisory Committee: Celgene Corporation, Millennium Pharmaceuticals Inc; Speakers Bureau: Celgene Corporation, Medtronic Inc, Millennium Pharmaceuticals Inc. Dr Ghobrial — Advisory Committee: Celgene Corporation, Novartis Pharmaceuticals Corporation; Speakers Bureau: Celgene Corporation, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation. Dr Lonial — Advisory Committee, Consulting Agreements and Paid Research: Bristol-Myers Squibb Company, Celgene Corporation, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation. Ms Richards — Advisory Committee: Millennium Pharmaceuticals Inc; Speakers Bureau: Celgene Corporation, Millennium Pharmaceuticals Inc. Ms Major Campos — Advisory Committee: Pfizer Inc; Speakers Bureau: Genentech BioOncology, Genomic Health Inc. Dr Rugo — Speakers Bureau: AstraZeneca Pharmaceuticals LP. Dr Swain — Paid Research: Bristol-Myers Squibb Company, Genentech BioOncology; Paid Travel: Sanofi-Aventis. Ms Culkin — Advisory Committee and Speakers Bureau: Genentech BioOncology, Lilly USA LLC; Consulting Agreement: Lilly USA LLC. Dr DiSalvo — Advisory Committee and Speakers Bureau: Genentech BioOncology; Speakers Bureau: Sanofi-Aventis. Dr Lara — Consulting Agreements: Eisai Inc, Genentech BioOncology, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc; Paid Research: Bayer HealthCare Pharmaceuticals, Exelixis Inc, GlaxoSmithKline, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi-Aventis; Speakers Bureau: Genentech BioOncology, Pfizer Inc. Dr Riely — Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc.
EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: Abraxis BioScience, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff, planners, managers and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This program is supported by educational grants from Abraxis BioScience, Biogen Idec, Cephalon Inc, Genentech BioOncology, Millennium Pharmaceuticals Inc and OSI Oncology.
Hardware/Software Requirements:
An Internet connection that is at least 28.8 Kbps
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
Macromedia Flash plug-in 6.0 or greater
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: October 2010
Expiration date: October 2011
-
Special Feature
-
Non-Hodgkin’s Lymphomas and Chronic Lymphocytic Leukemia Symposium with Drs Czuczman and Gregory, Ms Downs and Ms Goodrich
-
Multiple Myeloma Symposium with Drs Ghobrial and Lonial, Ms Faiman and Ms Richards
|
-
Breast Cancer Symposium with Drs Rugo and Swain, Ms Major Campos and Ms McKenney
-
Non-Small Cell Lung Cancer Symposium with Drs Lara, Riely and DiSalvo and Ms Culkin
|
-
Special Q & A Sessions Discussing Additional Audience Questions
Non-Hodgkin's Lymphomas and Chronic Lymphocytic Leukemia
Transcript with Amy Goodrich, CRNP-AC
discussing additional audience questions
from an interview occurring 9/14/10.
Download full transcript (48 KB, pdf format)
Multiple Myeloma
Transcript with Tiffany Richards, MS, ANP-BC, AOCNP discussing additional audience questions
from an interview occurring 9/17/10.
Download full transcript (52 KB, pdf format) |
Breast Cancer
Transcript with Maureen Major Campos, RN, MS discussing additional audience questions from an interview occurring 9/24/10.
Download full transcript (56 KB, pdf format)
Non-Small Cell Lung Cancer
Transcript with Ann Culkin, RN, OCN
discussing additional audience questions
from an interview occurring 9/24/10.
Download full transcript (48 KB, pdf format) |
-
Select Publications
-
Faculty: Non-Hodgkin’s Lymphomas and Chronic Lymphocytic Leukemia
Myron S Czuczman, MD
Head, Lymphoma/Myeloma
Service; Head, Lymphoma
Translational Research
Laboratory, Roswell Park
Cancer Institute; Associate
Professor of Medicine
School of Medicine and
Biomedical Sciences
University at Buffalo
Buffalo, New York
Lisa H Downs, MSN, CRNP
Coordinator
Lymphoma Program, Hospital
of the University of Pennsylvania
Philadelphia, Pennsylvania
|
Amy Goodrich, CRNP-AC
Nurse Practitioner
Johns Hopkins Kimmel
Cancer Center
Baltimore, Maryland
Stephanie A Gregory, MD
The Elodia Kehm Chair of Hematology
Professor of Medicine
Director, Section of Hematology
Rush University Medical Center
Rush University
Chicago, Illinois |
-
Multiple Myeloma
Beth Faiman, RN, MSN, APRN-BC, AOCN
Pre-Doctoral Research Fellow
Case Western Reserve University
Nurse Practitioner
Taussig Cancer Institute
The Cleveland Clinic
Cleveland, Ohio
Irene M Ghobrial, MD
Assistant Professor in Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts |
Sagar Lonial, MD
Associate Professor
Hematology and Medical Oncology
Director of Translational Research
B-Cell Malignancy Program
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Tiffany Richards, MS, ANP-BC, AOCNP
Nurse Practitioner
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas |
-
Breast Cancer
Maureen Major Campos, RN, MS
Breast Center Program
Manager, Smilow Cancer
Hospital at Yale New Haven
New Haven, Connecticut
Susan A McKenney, MSN, APRN, BC, OCN
Associate Professor
Department of Surgery
School of Medicine and School of Nursing
University of North Carolina
Director for Clinical Practice
and Program Development
North Carolina Cancer Hospital
Chapel Hill, North Carolina |
Hope S Rugo, MD
Clinical Professor of Medicine
Director, Breast Oncology
and Clinical Trials Education
University of California
San Francisco,
Helen Diller Family
Comprehensive Cancer Center
San Francisco, California
Sandra M Swain, MD
Medical Director
Washington Cancer Institute
Washington Hospital Center
Professor of Medicine
Georgetown University
Washington, DC
|
-
Non-Small Cell Lung Cancer
Ann Culkin, RN, OCN
Clinical Nurse
Thoracic Oncology Service
Memorial Sloan-Kettering Cancer Center
New York, New York
Wendye DiSalvo, DNP, APRN, AOCN
Family Nurse Practitioner
Interim Clinical Director of Nursing
Norris Cotton Cancer Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire |
Primo N Lara Jr, MD
Professor of Medicine
Associate Director of Translational Research
University of California
Davis Cancer Center
Sacramento, California
Gregory J Riely, MD, PhD
Assistant Attending
Memorial Sloan-Kettering Cancer Center
New York, New York |
|
